Scientists from the Yale University have found a new genetic marker which can predict the risk of developing ovarian cancer.
The research team showed that a variant of the KRAS oncogene was present in 25 percent of all ovarian cancer patients.
New Breast and Ovarian Cancer Susceptibility Gene Identified
Around 15 years ago it was found that the genes BRCA1 and BRCA2 confer high risks for breast and ovarian cancer
Advertisement
This variant was also found in 61 percent of ovarian cancer patients with a family history of breast and ovarian cancer, suggesting that it could be a new marker of ovarian cancer risk for these families, according to the researchers.
"For many women out there with a strong family history of ovarian cancer who previously have had no identified genetic cause for their family's disease; this might be it for them," said Joanne B. Weidhaas, associate professor of therapeutic radiology, and co-senior author of the study.
![Drink Tea to Cut Ovarian Cancer Risk]( "Drink Tea to Cut Ovarian Cancer Risk")
A new study found drinking tea can decrease the risk of ovarian cancer.
"Our findings support that the KRAS-variant is an new genetic marker of ovarian cancer risk," she added.
To confirm that the KRAS-variant was a genetic marker of ovarian cancer risk, Weidhaas and co-senior author Frank Slack studied women with ovarian cancer who also had evidence of a hereditary breast and ovarian cancer syndrome.
All these women had strong family history of cancer, but only half in their study had known genetic markers of ovarian cancer risk, BRCA1 or BRCA2 mutations.
Unlike women with BRCA mutations who develop ovarian cancer at a younger age, women with the KRAS-variant tend to develop cancer after menopause.
Because ovarian cancer is difficult to diagnose and thus usually found at advanced stages, finding new markers of increased ovarian cancer risk is critical, note the researchers.
The research was published in the July 20, 20010 edition of the journal Cancer Research.
Source: ANI
Drink Tea to Cut Ovarian Cancer Risk
A new study found drinking tea can decrease the risk of ovarian cancer.
Advertisement
"Our findings support that the KRAS-variant is an new genetic marker of ovarian cancer risk," she added.
To confirm that the KRAS-variant was a genetic marker of ovarian cancer risk, Weidhaas and co-senior author Frank Slack studied women with ovarian cancer who also had evidence of a hereditary breast and ovarian cancer syndrome.
All these women had strong family history of cancer, but only half in their study had known genetic markers of ovarian cancer risk, BRCA1 or BRCA2 mutations.
Unlike women with BRCA mutations who develop ovarian cancer at a younger age, women with the KRAS-variant tend to develop cancer after menopause.
Because ovarian cancer is difficult to diagnose and thus usually found at advanced stages, finding new markers of increased ovarian cancer risk is critical, note the researchers.
The research was published in the July 20, 20010 edition of the journal Cancer Research.
Source: ANI
New Approach May Help to Detect Ovarian Cancer Early
A new screening approach to detect early stage ovarian cancer in post-menopausal women has proven promising, researchers said of results to a study released Thursday.
Advertisement
Researchers Find an Antibody to Improve Ovarian Cancer TreatmentAustrian researchers have found an antibody that could be used to step up the fight against ovarian cancer -- a major killer for women. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The new study uncovers the efficacy of fixed-duration combination treatment in patients with high-risk leukemia.
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable